SYGNIS AG receives binding commitment for the purchase of shares
Capital increase to finance Innova Biosciences acquisition
SYGNIS AG received a binding commitment for the purchase of shares up to a total of EUR 3.5 million as part of the previously announced cash capital increases to finance the acquisition of Innova Biosciences Ltd. Under the terms of the agreement signed today, the investor has committed to purchase up to 2,536,000 new shares at a price of EUR 1.38 per new share. The obligation is subject to the condition that the DAX closing price on the settlement day is not more than 10% lower than the DAX closing price as of today.
“We are delighted by the positive feedback on the planned acquisition of Innova Biosciences Ltd. and the great support we experience from investors for this important strategic transaction,” Pilar de la Huerta, Co-CEO and CBDO of SYGNIS, said.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.